På Novocures egne sider står det følgende:
https://www.novocure.com/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma/
"The median overall survival was 18.2 months (95% CI 12.1-25.8) across all patients treated with NovoTTF-100L plus chemotherapy. The median overall survival was 21.2 months for patients with epithelioid MPM (n=53) and 12.1 months for patients with non-epithelioid MPM (n=21). More than half, 62 percent, of patients (n=80) enrolled in the STELLAR trial who used NovoTTF-100L plus chemotherapy were still alive at one year. The disease control rate in patients with at least one follow-up CT scan performed (n=72) was 97 percent. 40 percent of patients had a partial response, 57 percent had stable disease, and 3 percent had progressive disease. The median progression free survival was 7.6 months.
In addition, the STELLAR trial demonstrated that NovoTTF-100L could be combined with chemotherapy. There was no increase in serious systemic adverse events when NovoTTF-100L was added to chemotherapy. Mild-to-moderate skin irritation was the most common device-related side effect with NovoTTF-100L."
Følgende ble rapportert fra Targovax på MPM for ca år siden:
Responses observed in three out of six patients
Recruitment into the randomized part of the trial underway
Oslo, Norway, 2 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces encouraging results from its phase I/II trial of ONCOS-102 in mesothelioma, in combination with standard of care chemotherapy, in which clinical responses were observed in three out of the first six patients.
Og med responses menes altså PR eller SD
“Now, overall response rate has been evaluated for all six patients in the safety cohort after six months. Three out of the six patients (50%) responded, with one patient showing a partial response and two patients showing stable disease, according to the Response Evaluation Criteria In Solid Tumors guidelines, RECIST 1.1.”
Mine kommentarer til det over.
Det ser ut til at hvor kreften oppstår er avgjørende for resultatet, de som er epitheloid har svært god overlevelse, på 21 mnd, mens de som er non-epitheloid har det samme som SoC.
Videre er det Novocure kaller DCR (Disease Control Rate) og det Targovax omtaler som responses svært god for Novocure, ut fra det jeg kan skjønne. Men det er jo ikke sikkert avlesning er gjort på samme måte.
Det er også viktig å understreke at pasientpopulasjon, hvor syke de er, neppe er helt sammenlignbar heller.
Poenget mitt er at det virker å være en ny førstelinjebehandling i Mesotheliom, hvor OS er økt fra 12 til 18 mnd. Og spørsmålet er hva det har å si for Targovax sin konkurransesituasjon på den indikasjonen.
